Core Insights - argenx reported preliminary full-year 2025 global product net sales of $4.15 billion, reflecting a year-over-year growth of 90%, with fourth quarter sales contributing approximately $1.29 billion [1][15] - The company aims to impact over 50,000 patients globally with its medicines and has set strategic priorities for 2026, including expanding the use of VYVGART and advancing its pipeline towards Vision 2030 [4][3] Financial Performance - Preliminary global product net sales for the fourth quarter of 2025 were approximately $1.29 billion, while full-year sales reached $4.15 billion [15][16] - The reported growth of 90% year-over-year indicates strong market performance and demand for argenx's products [1] Product Pipeline and Development - VYVGART continues to lead the growth in the market for myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with around 19,000 patients currently on treatment [3][4] - The company has four registrational readouts expected in 2026, including the first for empasiprubart, which is part of the next wave of commercial launches planned for 2027 [1][3] - By the end of 2026, argenx anticipates having a total of 10 clinical-stage molecules, with three new molecules entering Phase 1 trials [1][8] Strategic Priorities for 2026 - The company aims to broaden the adoption of VYVGART and unlock new opportunities through potential label expansions, including a launch for AChR-Ab seronegative gMG expected by the end of 2026 [4][10] - argenx is focused on shaping the long-term future of FcRn medicines by advancing new pipeline candidates and innovative delivery modalities [5][7] - The strategic priorities include delivering the next wave of immunology innovation, with empasiprubart and a diversified pipeline of first-in-class molecules [5][8] Leadership Changes - Upcoming leadership transitions include Karen Massey becoming the new Chief Executive Officer, while Tim Van Hauwermeiren will transition to a non-Executive Director role [13][14] - These changes are subject to shareholder approval at the Annual General Meeting scheduled for May 6, 2026 [13]